A New Method to Model and Predict Progression Free Survival Based on Tumor Growth Dynamics

CPT Pharmacometrics Syst Pharmacol. 2020 Mar;9(3):177-184. doi: 10.1002/psp4.12499. Epub 2020 Mar 12.

Abstract

Progression-free survival (PFS) has been increasingly used as a primary endpoint for early clinical development. The aim of the present work was to develop a model where target lesion dynamics and risk for nontarget progression are jointly modeled for predicting PFS. The model was developed based on a pooled platinum-resistant ovarian cancer dataset comprising four different treatments and a wide range of dose levels. The target lesion progression was derived from tumor growth dynamics based on the Response Evaluation Criteria in Solid Tumors (RECIST) criteria. The nontarget progression hazard was correlated to the first derivative of target lesion tumor size with respect to time. The PFS time was determined by the first occurring event, target lesion progression, or nontarget progression. The final joint model not only captured target lesion tumor growth dynamics but also predicted PFS well. A similar approach can potentially be used to predict PFS in future oncology studies.

Publication types

  • Clinical Trial, Phase I
  • Clinical Trial, Phase II
  • Comparative Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Biomarkers, Tumor / metabolism
  • CA-125 Antigen / immunology
  • Decision Making
  • Disease Progression
  • Doxorubicin / pharmacology*
  • Doxorubicin / therapeutic use
  • Drug Resistance, Neoplasm
  • Female
  • Humans
  • Membrane Proteins / antagonists & inhibitors
  • Membrane Proteins / immunology
  • Models, Theoretical
  • Organoplatinum Compounds / pharmacology*
  • Organoplatinum Compounds / therapeutic use
  • Ovarian Neoplasms / drug therapy*
  • Ovarian Neoplasms / mortality
  • Platinum / pharmacology*
  • Platinum / therapeutic use
  • Predictive Value of Tests
  • Progression-Free Survival
  • Response Evaluation Criteria in Solid Tumors
  • Sodium-Phosphate Cotransporter Proteins, Type IIb / antagonists & inhibitors
  • Sodium-Phosphate Cotransporter Proteins, Type IIb / immunology
  • Software
  • Topoisomerase II Inhibitors / pharmacology*
  • Topoisomerase II Inhibitors / therapeutic use
  • Treatment Outcome
  • Tumor Burden / drug effects*

Substances

  • Biomarkers, Tumor
  • CA-125 Antigen
  • MUC16 protein, human
  • Membrane Proteins
  • Organoplatinum Compounds
  • SLC34A2 protein, human
  • Sodium-Phosphate Cotransporter Proteins, Type IIb
  • Topoisomerase II Inhibitors
  • Platinum
  • Doxorubicin